OrbiMed’s Jazz Pharmaceuticals JAZZ Stock Holding History

OrbiMed’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-100,000	Closed	-$15.6M	–	148
2017 Q2	$15.6M	Buy	+100,000	New	+$15.3M	0.16%	88
2014 Q3	–	Sell	-150,000	Closed	-$22.1M	–	139
2014 Q2	$22.1M	Buy	+150,000	New	+$20.8M	0.26%	61

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's JAZZ Position: Q4 2018 in Review

OrbiMed sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 884,000 shares — an estimated $149M sold.

OrbiMed first reported a position in JAZZ in Q2 2013 and held it in 22 quarters. The position peaked at $179M in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

OrbiMed reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
OrbiMed sold 884,000 Jazz Pharmaceuticals shares in Q4 2018, an estimated $149M.
OrbiMed first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 22 quarters.
OrbiMed's Jazz Pharmaceuticals position peaked at $179M in Q2 2018.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on OrbiMed's 13F filing for Q4 2018, filed 14 Feb 2019.